Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY) (SERENITY)

16 de novembro de 2026 atualizado por: argenx

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Participants With Sjogren's Disease-Associated Sensorimotor or Sensory Polyneuropathy

This study aims to assess the efficacy and safety of efgartigimod PH20 in adults with Sjogren's Disease (SjD) associated with nerve damage. The study will assess how efgartigimod PH20 affects symptoms of SjD specifically linked to the peripheral nervous system; the safety and tolerability of efgartigimod PH20; and whether receiving efgartigimod PH20 affects the participant's quality of life.

Visão geral do estudo

Descrição detalhada

The study will be conducted in adult participants with moderate-to-severe SjD and SjD-associated sensorimotor polyneuropathy (SMPN) or sensory polyneuropathy (SPN). The study consists of two parts. Part A is a randomized, double-blinded, placebo-controlled, parallel-group treatment period designed to evaluate the efficacy and safety of efgartigimod hyaluronidase (PH20) subcutaneously (SC) or placebo. Following the completion of part A, the double-blinded treatment period (DBTP) participants will enter part B, an open-label treatment period (OLTP) to assess long-term safety, tolerability, and durability of response of efgartigimod PH20 SC.

The overall study duration will be up to 108 weeks for each participant.

Tipo de estudo

Intervencional

Inscrição (Estimado)

75

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Florida
      • Sarasota, Florida, Estados Unidos, 34239
        • Recrutamento
        • Sarasota Arthritis Research Center
        • Contato:
        • Investigador principal:
          • Jaishree Manohar, Dr.
      • Tampa, Florida, Estados Unidos, 33614
        • Recrutamento
        • Vantage Clinical Trials Tampa
        • Contato:
        • Investigador principal:
          • Edgard Janer, Dr.
    • Michigan
      • Sterling Heights, Michigan, Estados Unidos, 48313
        • Recrutamento
        • Revive Research Institute Inc
        • Contato:
        • Investigador principal:
          • Syed Husain, Dr.

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF
  • Meets the following SjD criteria: Fulfilled American College of Rheumatology and the European Alliance of Associations for Rheumatology classification 2016 SjD criteria before screening; Moderate-to-severe disease defined as a ESSDAI ≥ 5 or clinESSDAI ≥ 6 with PNS domain score of ≥ 5 (ie, a score of at least low activity) at screening; Anti-Ro/SS-A positive at a central laboratory at screening
  • Meets the following SjD-associated polyneuropathy criteria: Diagnosis of SjD-associated SMPN, SPN or sensory ganglionopathy, with neuropathy duration ≤ 5 years at screening and signs of active neuropathic disease development within the last 12 months; patients with co-existing SjD-associated small fiber neuropathy are eligible; No alternative diagnosis of neuropathy etiology; Total mTCNS ≥ 6 at screening; mTCNS sensory test score <level 3 at screening (does not apply to sensory ganglionopathy cohort where any severity is acceptable)

Exclusion Criteria:

  • Besides the indication under study, known medical conditions that would interfere with an accurate assessment of clinical symptoms of SjD-associated SMPN or SPN or gangliopathy, confound the study results, or puts the participant at undue risk.
  • Associated (also known as secondary) SjD, defined as overlap with another autoimmune rheumatic or systemic inflammatory condition (eg, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, or idiopathic inflammatory myopathy).
  • Active fibromyalgia which is not adequately controlled in the judgment of the investigator, or participant is receiving fibromyalgia treatment that has not been stable treatment for at least 12 weeks before screening.
  • An alternative etiology for SMPN/SPN/sensory ganglionopathy or insufficient evidence of the diagnosis.
  • Any severe SjD manifestation or other health condition not adequately controlled at screening or baseline that may put the participant at undue risk based on the investigator's opinion.
  • Comorbidities (eg, asthma, chronic obstructive pulmonary disease) which have required 3 or more courses of systemic (oral, IV, or IM) glucocorticoids within the previous 12 months.
  • History of malignancy unless considered cured by adequate treatment with no evidence of recurrence for ≥ 3 years; before first IMP administration.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Double-blinded treatment period (DBTP): Efgartigimod PH20 SC

Participants receiving efgartigimod PH20 SC during the double-blinded treatment period

subcutaneous efgartigimod PH20 SC given by prefilled syringe

Comparador de Placebo: Double-blinded treatment period (DBTP): Placebo PH20 SC

Participants receiving placebo PH20 SC during the double-blinded treatment period

subcutaneous placebo PH20 SC given by prefilled syringe

Experimental: Open-label treatment period (OLTP)

Participants receiving efgartigimod PH20 SC during the open-label treatment period

subcutaneous efgartigimod PH20 SC given by prefilled syringe

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change from baseline in modified Toronto Clinical Neuropathy Score (mTCNS) total score at the end of Part A
Prazo: Up to 48 weeks

The mTCNS (modified Toronto Clinical Neuropathy Score) is a clinician-reported outcome measure derived from the original TCNS to improve sensitivity to early and mild neuropathy and to enhance feasibility and consistency inclinical research settings. The total mTCNS score is calculated as the sum of the symptom and sensory subscores, yielding a total possible score range of 0 to 33, with higher scores indicating greater neuropathy severity.

Up to 48 weeks

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change from baseline in modified Toronto Clinical Neuropathy Score (mTCNS) total score over time
Prazo: up to 96 weeks

The mTCNS (modified Toronto Clinical Neuropathy Score) is a clinician-reported outcome measure derived from the original TCNS to improve sensitivity to early and mild neuropathy and to enhance feasibility and consistency inclinical research settings. The total mTCNS score is calculated as the sum of the symptom and sensory subscores, yielding a total possible score range of 0 to 33, with higher scores indicating greater neuropathy severity.

up to 96 weeks
Change from baseline in Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) total score at the end of part A and over time
Prazo: up to 96 weeks

The Norfolk QoL-DN is a patient-reported outcome (PRO) instrument designed to assess neuropathy symptom severity and the impact of peripheral neuropathy on participants' ability to complete activities of daily living (ADLs). The Norfolk QoL-DN consists of 35 items that assess the presence and severity of sensory symptoms (eg, numbness, tingling, pain), motor and balance difficulties, and the extent to which neuropathy interferes with daily activities, sleep, work, and social functioning.

up to 96 weeks
Change from baseline in clinical EULAR Sjögren's Syndrome Disease Activity Index (clinESSDAI) score at the end of part A and over time
Prazo: up to 96 weeks

The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) was designed to measure systemic disease activity in patients with SjD. The ESSDAI consists of 12 domains, and the final score falls between 0 (no disease activity) and, theoretically, 123 (maximum disease activity). Clinical EULAR Sjögren's Syndrome Disease Activity Index (clinESSDAI) includes all ESSDAI domains except the biological domain. The clinical domains in clinESSDAI have different weights than in ESSDAI.

up to 96 weeks
Change from baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at the end of part A and over time
Prazo: up to 96 weeks

The ESSDAI was designed to measure systemic disease activity in patients with SjD. The ESSDAI consists of 12 domains, and the final score falls between 0 (no disease activity) and, theoretically, 123 (maximum disease activity).

up to 96 weeks
Proportion of participants with low disease activity (clinESSDAI < 5) at the end of part A and over time
Prazo: up to 96 weeks

The ESSDAI was designed to measure systemic disease activity in patients with SjD. The ESSDAI consists of 12 domains, and the final score falls between 0 (no disease activity) and, theoretically, 123 (maximum disease activity). clinESSDAI includes all ESSDAI domains except the biological domain. The clinical domains in clinESSDAI have different weights than in ESSDAI.

up to 96 weeks
Incidence of AEs
Prazo: Up to 104 weeks

Incidents are identified by measuring clinically significant changes in vital signs, physical examination, ECG, and clinical laboratory safety evaluations.

Up to 104 weeks
Change from baseline in Neuropathic Pain Questionnaire (NPQ) at the end of part A and over time
Prazo: up to 96 weeks

The NPQ is a self-administered PRO used to characterize the qualitative features of neuropathic pain. Responses are combined using a predefined scoring algorithm to generate a summary score reflecting the presence and prominence of neuropathic pain features.

up to 96 weeks
Change from baseline in the Difficulty Thinking Numerical Rating Scale (NRS) at the end of part A and over time
Prazo: up to 96 weeks

The Difficulty Thinking Numerical Rating Scale (NRS) is a SjD-specific symptom severity diary that has been developed specifically for the purpose of assessing disease severity in participants with SjD. An 11-point Likert response scale is used from 0 (no difficulty thinking) to 10 (worst possible difficulty thinking).

up to 96 weeks
Change from baseline in Patient Global Impression of Severity (PGIS) scores at the end of part A and over time
Prazo: up to 96 weeks

The PGIS of neuropathy severity is a single-item questionnaire that asks participants to provide a self-assessment of their overall neuropathy severity, using a 5-point scale.

up to 96 weeks
Change from baseline in Patient Global Impression of Change (PGIC) scores at the end of part A and over time
Prazo: up to 96 weeks

The PGIC of neuropathy severity is a single-item questionnaire that asks the participant to provide a self-assessment of change in their neuropathy severity using a 7-point scale compared to just before the participant started taking the IMP.

up to 96 weeks
Change from baseline in Clinical Global Impression of Severity (CGIS) scores at the end of part A and over time
Prazo: up to 96 weeks

The CGI of SjD-associated SMPN or SPN severity is a 1-item questionnaire that asks the clinician to provide an assessment of their patients' neuropathy severity on a 5-point scale at the time of the visit.

up to 96 weeks
Change from baseline in Clinical Global Impression of Change (CGIC) scores at the end of part A and over time
Prazo: up to 96 weeks

The CGIC of SjD-associated SMPN or SPN severity is a 1-item questionnaire that asks the clinician to provide the overall change in their patients' neuropathy severity on a 7-point scale, compared to just before participant started taking the IMP.

up to 96 weeks
Change from baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) scores at the end of part A and over time
Prazo: up to 96 weeks

The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) scale assesses fatigue and its impact on patient's everyday lives, with a 7-day recall. It comprises 13 items, with responses of each of the items using a 5-point Likert scale ranging from 1 (Not at all) to 5 (Very much).

up to 96 weeks

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

9 de outubro de 2026

Conclusão Primária (Estimado)

28 de julho de 2028

Conclusão do estudo (Estimado)

28 de julho de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

29 de julho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

7 de agosto de 2026

Primeira postagem (Real)

12 de agosto de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

19 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

16 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • ARGX-113-15-SJD-2003
  • 2026-526218-10-00 (Ctis)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever